ArticleNature communications2025
Engineered Spirulina platensis for treating rheumatoid arthritis and restoring bone homeostasis.
Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Modulation of innate and adaptive immunity by pH-responsive nanozyme-like nanoparticles with high mobility for rheumatoid arthritis alleviation.Bioactive materials · 2026Article
- Engineered Microalgae Promoting Angiogenesis for Diabetic Bone Regeneration.Advanced healthcare materials · 2026Article
- Microfluidic-based biomimetic mitochondrial nanocomposite for targeted immunotherapy of rheumatoid arthritis via mitochondrial transplantation.Materials today. Bio · 2026Article
- Microalgal Active Peptides: Advances in Preparation, Efficacy, and Mechanisms of Hypoglycemic Action.Journal of food science · 2026Review
- Dietary Supplementation withAnimals : an open access journal from MDPI · 2026Article
- Gut microbiota dysbiosis and joint diseases: advances in the gut-joint axis.Frontiers in immunology · 2026Review
- Multifunctional nanotherapeutics reprogramming the immunopathological landscape for rheumatoid arthritis therapy.Materials today. Bio · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Rheumatoid arthritis (RA) is characterized by massive intra-articular infiltration of pro-inflammatory macrophages, leading to articular immune dysfunction, severe synovitis, and ultimately joint erosion. Comprehensive remodeling of articular immune homeostasis and bone homeostasis is essential for alleviating RA. Here we report on Spirulina platensis (SP), a natural microorganism commercially farmed worldwide as a food, as an efficient regulator of both synovial inflammation and osteoclast differentiation in male RA mouse models. SP reduces excessive reactive oxygen species and downregulates pro-inflammatory cytokines in synovial macrophages. Moreover, SP reprograms pro-inflammatory M1-like macrophages to anti-inflammatory M2-like phenotype, suppressing synovitis and remodeling redox balance. Notably, SP inhibits osteoclast activation effectively and blocks the progression of bone erosion. SP is then engineered with macrophage membranes (SP@M) to enable immune evasion and RA-targeting in vivo. SP@M increases LC3-mediated autophagy as well as strengthens ubiquitin-mediated proteasomal degradation toward KEAP1, which promotes the expression and nuclear translocation of NRF2. The NRF2 further activates antioxidant enzymes to terminate macrophages-initiated pathological cascades and reestablish intra-articular immune homeostasis, conferring a bone recovery and chondroprotective effect in collagen-induced arthritis mouse models. This work shows the therapeutic activity of FDA-approved functional food of SP in suppressing synovial inflammation and osteoclast differentiation, offering an off-the-shelf strategy for RA treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.